diff --git a/inbox/queue/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md b/inbox/queue/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md index 7e035362c..0646779b1 100644 --- a/inbox/queue/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md +++ b/inbox/queue/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md @@ -51,7 +51,7 @@ intake_tier: research-task **What I expected but didn't find:** Specific clinical screening criteria being adopted in the AUD trial context. The SEMALCO trial enrolled patients with AUD + obesity but the psychiatric screening criteria weren't prominently discussed in the results coverage. **KB connections:** -- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors]] — same paradox structure: the intervention that appears safe in controlled populations creates new risks in real-world deployment +- human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors — same paradox structure: the intervention that appears safe in controlled populations creates new risks in real-world deployment - [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — GLP-1 psychiatric safety monitoring faces the same challenge: the drug was approved for metabolic disease, being deployed in behavioral health without mental health-specific monitoring infrastructure **Extraction hints:** diff --git a/inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md b/inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md index f6a404557..4babccb11 100644 --- a/inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md +++ b/inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md @@ -63,7 +63,7 @@ intake_tier: research-task **KB connections:** - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — this meta-analysis substantially expands the claim's scope; should trigger a claim enrichment or new claim -- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — Belief 2 complication: a pharmacological intervention at the biological mechanism level shows population-scale behavioral change +- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate — Belief 2 complication: a pharmacological intervention at the biological mechanism level shows population-scale behavioral change **Extraction hints:** 1. **High-priority claim candidate:** "GLP-1 receptor agonists reduce alcohol consumption and AUD risk across diverse populations with a 28-36% reduction in AUD-related outcomes, supported by a meta-analysis of 14 studies and 5.26M patients" diff --git a/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md b/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md index e81478d69..ad209a73c 100644 --- a/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md +++ b/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md @@ -63,7 +63,7 @@ intake_tier: research-task **KB connections:** - [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — if GLP-1 can treat SUD pharmacologically via metabolic prescribers, it partially bypasses the specialist shortage -- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — Belief 2 complication: pharmacological modulation of reward circuits challenges the behavioral primacy of addiction treatment +- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate — Belief 2 complication: pharmacological modulation of reward circuits challenges the behavioral primacy of addiction treatment **Extraction hints:** 1. Do not write a claim yet — evidence is too fragmented across disorders to make a unified claim diff --git a/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md b/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md index 0c07ff6f1..84a74d2fe 100644 --- a/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md +++ b/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md @@ -58,8 +58,8 @@ intake_tier: research-task **KB connections:** - [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem]] — if GLP-1 reduces depression risk, it may address a second pathway to the loneliness/social health crisis -- [[the mental health supply gap is widening not closing because demand outpaces workforce growth]] — if GLP-1 has antidepressant properties, it could expand behavioral health capacity via prescribers already in the metabolic medicine space -- [[prescription digital therapeutics failed as a business model]] — GLP-1 may be doing what DTx failed to do: reaching mental health patients through non-psychiatric prescribing channels +- the mental health supply gap is widening not closing because demand outpaces workforce growth — if GLP-1 has antidepressant properties, it could expand behavioral health capacity via prescribers already in the metabolic medicine space +- prescription digital therapeutics failed as a business model — GLP-1 may be doing what DTx failed to do: reaching mental health patients through non-psychiatric prescribing channels **Extraction hints:** 1. New claim candidate: "Semaglutide is associated with 44% lower risk of worsening depression in patients with pre-existing depression or anxiety, suggesting GLP-1 receptor agonism produces psychiatric protective effects beyond metabolic outcomes" diff --git a/inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md b/inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md index 782b139d3..d2723f1d7 100644 --- a/inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md +++ b/inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md @@ -60,8 +60,8 @@ intake_tier: research-task **KB connections:** - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — this finding extends GLP-1 beyond metabolic disease -- [[the mental health supply gap is widening not closing because demand outpaces workforce growth]] — if GLP-1 treats AUD pharmacologically, it potentially bypasses the therapist workforce constraint -- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — requires qualification for addiction medicine subpopulation +- the mental health supply gap is widening not closing because demand outpaces workforce growth — if GLP-1 treats AUD pharmacologically, it potentially bypasses the therapist workforce constraint +- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate — requires qualification for addiction medicine subpopulation **Extraction hints:** 1. New claim: "Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in RCT, extending GLP-1 therapeutic scope from metabolic to behavioral health" diff --git a/inbox/queue/2026-05-03-omada-glp1-flex-care-employer-market-context.md b/inbox/queue/2026-05-03-omada-glp1-flex-care-employer-market-context.md index d227fe736..b9d38004a 100644 --- a/inbox/queue/2026-05-03-omada-glp1-flex-care-employer-market-context.md +++ b/inbox/queue/2026-05-03-omada-glp1-flex-care-employer-market-context.md @@ -58,8 +58,8 @@ Is behavioral data and outcomes data sufficient for defensibility, or does the t **KB connections:** - [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]] — Belief 4 test case -- [[AI-native health companies achieve 3-5x the revenue productivity of traditional health services]] — Omada FY2025 data point -- [[consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway]] — Flex Care is an employer-level version of the same dynamic +- AI-native health companies achieve 3-5x the revenue productivity of traditional health services — Omada FY2025 data point +- consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway — Flex Care is an employer-level version of the same dynamic **Extraction hints:** 1. Not a standalone claim yet — need adoption data before claiming market validation diff --git a/inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md b/inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md index faa60bc38..29d84a7f3 100644 --- a/inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md +++ b/inbox/queue/2026-05-03-smc-expert-reactions-semalco-trial-caveats.md @@ -55,8 +55,8 @@ intake_tier: research-task **What I expected but didn't find:** Discussion of what "Phase 3 trials underway" means specifically — design, timeline, sponsor. The trial NCT07223983 (SEMA for AUD after bariatric surgery) appeared in search but is a different design from the population-level Phase 3 needed. **KB connections:** -- [[AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI-first screening viable]] — contrast: AI achieves high evidence quickly, GLP-1 behavioral health requires careful phase progression -- [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without pricing power]] — GLP-1 AUD won't face the same model failure (it's a drug, not a DTx) but the reimbursement path for addiction indication is uncertain +- AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI-first screening viable — contrast: AI achieves high evidence quickly, GLP-1 behavioral health requires careful phase progression +- prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without pricing power — GLP-1 AUD won't face the same model failure (it's a drug, not a DTx) but the reimbursement path for addiction indication is uncertain **Extraction hints:** 1. Use as the "limitations" section for any SEMALCO-based claim diff --git a/inbox/queue/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md b/inbox/queue/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md index b0d558377..b92906d2f 100644 --- a/inbox/queue/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md +++ b/inbox/queue/2026-05-03-vigibase-pharmacovigilance-glp1-psychiatric-signals.md @@ -64,7 +64,7 @@ intake_tier: research-task **KB connections:** - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — safety signal monitoring as market risk -- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic]] — GLP-1 addresses food reward pathways; eating disorder risk in vulnerable individuals is the mechanistic flip side +- Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic — GLP-1 addresses food reward pathways; eating disorder risk in vulnerable individuals is the mechanistic flip side **Extraction hints:** 1. No standalone claim yet — the evidence is too contradictory to write with confidence